Below are the most recent publications written about "RANK Ligand" by people in Profiles.
-
Thimmuri D, P A S, N P S, Khan A, Gawali B, Rajdev B, Adhikari C, V R, Sharma P, Naidu V. Hispolon inhibits RANKL induced osteoclast differentiation in vitro. Immunol Lett. 2021 03; 231:35-42.
-
Chitwood DG, Wang Q, Elliott K, Bullock A, Jordana D, Li Z, Wu C, Harcum SW, Saski CA. Characterization of metabolic responses, genetic variations, and microsatellite instability in ammonia-stressed CHO cells grown in fed-batch cultures. BMC Biotechnol. 2021 01 08; 21(1):4.
-
Biscetti F, Giovannini S, Straface G, Bertucci F, Angelini F, Porreca C, Landolfi R, Flex A. RANK/RANKL/OPG pathway: genetic association with history of ischemic stroke in Italian population. Eur Rev Med Pharmacol Sci. 2016 11; 20(21):4574-4580.
-
Meijome TE, Ekwealor JTB, Hooker RA, Cheng YH, Ciovacco WA, Balamohan SM, Srinivasan TL, Chitteti BR, Eleniste PP, Horowitz MC, Srour EF, Bruzzaniti A, Fuchs RK, Kacena MA. C-Mpl Is Expressed on Osteoblasts and Osteoclasts and Is Important in Regulating Skeletal Homeostasis. J Cell Biochem. 2016 04; 117(4):959-69.
-
Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, Tombal B, Damiao R, Marx G, Miller K, Van Veldhuizen P, Morote J, Ye Z, Dansey R, Goessl C. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol. 2013 Oct 20; 31(30):3800-6.
-
Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Dami?o R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, G?mez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012 Jan 07; 379(9810):39-46.
-
Fizazi K, Carducci M, Smith M, Dami?o R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011 Mar 05; 377(9768):813-22.
-
Nishida T, Emura K, Kubota S, Lyons KM, Takigawa M. CCN family 2/connective tissue growth factor (CCN2/CTGF) promotes osteoclastogenesis via induction of and interaction with dendritic cell-specific transmembrane protein (DC-STAMP). J Bone Miner Res. 2011 Feb; 26(2):351-63.
-
Manabe N, Kawaguchi H, Chikuda H, Miyaura C, Inada M, Nagai R, Nabeshima Y, Nakamura K, Sinclair AM, Scheuermann RH, Kuro-o M. Connection between B lymphocyte and osteoclast differentiation pathways. J Immunol. 2001 Sep 01; 167(5):2625-31.